APCCC 2024: Dosing of Radioligand Therapy in Special Situations And/or Toxicity urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
University of California prostate cancer experts will share clinical insights at the first annual PSMA Conference, “PSMA PET and RLT: Present and Future.”
Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.
ESMO 2023: Invited Discussant: Is More Always Better? urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
Treatment with the combination of lutetium Lu 177 vipivotide tetraxetan and enzalutamide led to an improvement in prostate-specific antigen progression-free survival vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer.